Stock Traders Purchase High Volume of Esperion Therapeutics Put Options (NASDAQ:ESPR)


Share on StockTwits

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 4,156 put options on the stock. This is an increase of approximately 4,275% compared to the average volume of 95 put options.

ESPR stock opened at $26.91 on Thursday. The business has a 50 day moving average price of $28.76 and a two-hundred day moving average price of $34.75. The company has a market cap of $750.17 million, a price-to-earnings ratio of -6.99 and a beta of 1.56. Esperion Therapeutics has a twelve month low of $23.90 and a twelve month high of $76.98.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($3.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.52) by $0.45. Esperion Therapeutics had a negative return on equity of 629.88% and a negative net margin of 46.15%. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.04 million. During the same period last year, the company earned ($2.52) earnings per share. The business’s revenue was up 290.7% compared to the same quarter last year. On average, equities analysts forecast that Esperion Therapeutics will post -4.38 EPS for the current fiscal year.

A number of equities research analysts have recently commented on ESPR shares. Bank of America dropped their price target on Esperion Therapeutics from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Thursday, October 15th. JPMorgan Chase & Co. started coverage on Esperion Therapeutics in a research report on Tuesday, September 29th. They set a “sell” rating and a $35.00 price target on the stock. Credit Suisse Group raised Esperion Therapeutics from a “neutral” rating to an “outperform” rating and set a $45.00 target price on the stock in a research report on Tuesday, November 10th. Finally, BidaskClub raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $77.38.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wasatch Advisors Inc. boosted its stake in shares of Esperion Therapeutics by 93.6% during the 3rd quarter. Wasatch Advisors Inc. now owns 2,409,683 shares of the biopharmaceutical company’s stock worth $89,568,000 after acquiring an additional 1,165,257 shares during the period. State Street Corp boosted its stake in shares of Esperion Therapeutics by 3.2% during the 3rd quarter. State Street Corp now owns 1,802,750 shares of the biopharmaceutical company’s stock worth $67,008,000 after acquiring an additional 55,054 shares during the period. Platinum Investment Management Ltd. boosted its stake in shares of Esperion Therapeutics by 1.8% during the 3rd quarter. Platinum Investment Management Ltd. now owns 866,681 shares of the biopharmaceutical company’s stock worth $32,215,000 after acquiring an additional 15,228 shares during the period. Rhenman & Partners Asset Management AB boosted its stake in shares of Esperion Therapeutics by 7.1% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 455,000 shares of the biopharmaceutical company’s stock worth $16,912,000 after acquiring an additional 30,000 shares during the period. Finally, Great West Life Assurance Co. Can boosted its stake in shares of Esperion Therapeutics by 12,650.6% during the 3rd quarter. Great West Life Assurance Co. Can now owns 211,660 shares of the biopharmaceutical company’s stock worth $89,000 after acquiring an additional 210,000 shares during the period.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Article: What are the reasons investors use put options?

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.